Evenamide Phase 3 Program: Study 023 (ENIGMA-TRS) evaluates the efficacy of add-on glutamate modulation in patients with documented treatment-resistant schizophrenia

20260 citationsJournal Articlegold Open Access

Authors

Good health and well-being

Published in: Neuroscience Applied

Volume 5, pp. 105757-105757

Field-Weighted Citation Impact: 0.00